Nuvo Research receives first three Pliaglis marketing licenses from E.U. countries
21:22 EDT 19 Jul 2012 | The Medical News
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that Galderma S.A. (Galderma), a global company dedicated to dermatology has received its first thr..
Original Article: Nuvo Research receives first three Pliaglis marketing licenses from E.U. countries
More From BioPortfolio on "Nuvo Research receives first three Pliaglis marketing licenses from E.U. countries"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
